Status:
NOT_YET_RECRUITING
MCRcI® Stem Cell Treatment for Diffuse Coronary Artery Disease
Lead Sponsor:
Honya Medical Inc
Collaborating Sponsors:
Chang Gung Memorial Hospital
Conditions:
Coronary Artery Disease
Eligibility:
All Genders
20-80 years
Phase:
PHASE1
Brief Summary
Safety evaluation of Intra-Coronary Administration of MCRcI® stem cells in Patients with Diffuse Coronary Artery Disease.
Eligibility Criteria
Inclusion
- Patients with Diffuse Coronary Artery Disease
- Age 20\~80
- Participants have received proper medication
- Canadian Cardiovascular Society class II- IV Angina.
Exclusion
- Age \<20 or \>80
- Pregnant or breast feeding
- Positive adventitious infection (such as HIV, hepatitis )
- History of Myocardial Infarction within past 3 months
- Severe aortic or mitral valve narrowing
- Short of breath unable to receive PCI examination or treatment
- Malignant tumor
- Hematopoietic dysplasia
- Severe organ disease with less than 1 year of life expectancy
- Chronic kidney disease with CCr\<20ml/min
- Kiney disease on renal dialysis.
Key Trial Info
Start Date :
December 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2026
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04052191
Start Date
December 1 2025
End Date
December 1 2026
Last Update
October 3 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
HONYA Medical Inc
Tainan, Taiwan, 74147